Surface-mounted pump
The problem of immune response at the infusion site is solved by introducing a filter into the patch pump, extending the pump usage time and improving the stability of insulin delivery and patient comfort.
Patent Information
- Application Number
- CN202380032775.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-17
- Filing Date
- 2023-04-05
- Publication Date
- 2024-11-22
AI Technical Summary
The existing patch insulin pumps can easily lead to immune responses at the infusion site during use, leading to problems such as pain, bleeding, infection, skin irritation, erythema, fat hypertrophy and fat atrophy, reducing insulin sensitivity and increasing the risk of hypoglycemia. , limits the wear time of the patch pump.
A patch pump consisting of a reservoir unit for storing therapeutic agents, a cannula with a subcutaneous delivery function and a fluid flow path, and a patch pump through the filter that filters the therapeutic agents before delivery Remove unwanted substances and reduce the occurrence of foreign body reactions.
The wear time of patch pumps is extended, problems related to the infusion site are alleviated, the risk of foreign body reaction is reduced, and the stability of insulin delivery and patient comfort is improved.
Smart Images

Figure CN119013059A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a patch pump for subcutaneously infusing a therapeutic agent into a patient and related methods. In particular, but not exclusively, the present invention relates to a patch pump for subcutaneously infusing insulin, heparin, apomorphine, arbidopa or levodopa and / or levodopa products into a patient. Background Art
[0002] For diabetics, insulin therapy is usually an important part of their treatment, helping to regulate blood sugar levels and store excess glucose for energy. There are two main modes of insulin delivery. The first mode includes syringes and injection pens, which are used to inject a certain dose of insulin, usually three to four times a day (especially depending on the type of diabetes and the patient's blood sugar level). Although these devices are simple and low in cost, acupuncture is required to deliver each dose of insulin. The second mode uses an infusion pump, sometimes referred to as an insulin pump, which delivers controlled doses of insulin throughout the day. Infusion pumps can be used to deliver insulin to patients continuously (basal dose), on demand (single dose) or at predetermined time intervals. Infusion pumps are more complicated and more expensive than syringes and pens, although they can, for example, be improved by programmable delivery schedules and require less acupuncture to regulate blood sugar levels.
[0003] The second mode is called continuous subcutaneous insulin infusion (CSII) therapy. The infusion pump system such as the patch pump or infusion set for CSII treatment can be worn by the patient. The system generally includes a combined infusion pump and a reservoir for accommodating insulin drugs (such as human insulin or simulated insulin), and a cannula (such as a polymer catheter or a metal needle) for inserting into the patient's subcutaneous area. In the case of an infusion set, a flexible tube can be connected to the infusion set that the patient wears. Once the cannula is inserted into the patient's body, it can remain in place for a period of time, i.e., a few days, to allow continuous delivery of insulin drugs. The wearing time of the patch pump currently recommended is two to three days, to avoid possible problems related to the patch pump itself or the infusion site. However, within the recommended wearing time, these problems may still occur, thereby causing the premature removal of the patch pump and more frequently rotating the position between the infusion sites (such as buttocks, abdomen and arms).
[0004] While the problems associated with patch pumps have been well studied and addressed in recent years, there is still a lack of understanding and solutions to addressing problems associated with the infusion site. Problems associated with the infusion site include pain, bleeding, infection, skin irritation, erythema, lipohypertrophy, and lipoatrophy. Problems at the infusion site can lead to the formation of scar tissue, which can reduce insulin sensitivity and increase the risk of hypoglycemia, as well as affect the patient's appearance. All of these issues can discourage patients from continuing to use their patch pumps, leading to poor patient outcomes.
[0005] It is known that the problem at the infusion site is the result of the immune response to the presence of the cannula and insulin medication in the body. The immune system responds by activating and promoting foreign body reaction (FBR), which is an inflammatory and fibrotic process that occurs when a foreign body is introduced into the body. In FBR, the cells of the immune system recognize foreign matter (unwanted biological, chemical or physical species present in the infusion solution) and attempt to degrade it, or isolate it from other parts of the body by forming a physical barrier to encapsulate the foreign matter. Because the immune system responds to the cannula and insulin medication inserted, FBR is a problem for increasing the wearing time of the patch pump in CSII therapy. This limitation hinders the realization of the full potential of CSII therapy.
[0006] Often, the presence of unwanted substances, whether biological, chemical or physical, in infusion solutions can have undesirable consequences for the patient.
[0007] It is an object of embodiments of the present invention to provide an improved patch pump that seeks to avoid FBR, increase the wear time of the infusion set, and / or at least alleviate one or more problems associated with known arrangements. Summary of the invention
[0008] The invention is defined by the appended claims.
[0009] The present invention provides a patch pump for delivering a therapeutic agent to a patient subcutaneously, the patch pump comprising: a reservoir unit configured to store a therapeutic agent; a delivery unit having a cannula arranged to deliver the therapeutic agent to the patient subcutaneously; a pump unit arranged to pump the therapeutic agent along a fluid flow path extending from the reservoir unit to the cannula; and a filter fixed in the fluid flow path and configured to filter the therapeutic agent before the therapeutic agent is delivered to the patient.
[0010] In some examples, the filter is secured within the reservoir unit. In some examples, the filter is secured within a fluid port of the reservoir unit.
[0011] In some examples, the reservoir unit is arranged to receive a therapeutic agent from an external source. In some examples, the reservoir unit includes a second fluid port for receiving the therapeutic agent from the external source. In some examples, the reservoir unit includes a single fluid port for releasing the therapeutic agent.
[0012] In some examples, the filter is fixed within the pump unit. In some examples, the battery unit includes a controller arranged to pump the therapeutic agent along a fluid flow path. In some examples, the controller has a non-volatile memory having instructions stored thereon for pumping the therapeutic agent according to a predetermined schedule. In some examples, the controller is configured to receive one or more instructions from an external device for operating the pump unit. In some examples, the battery unit includes a power supply for powering the pump unit. In some examples, the patch pump includes a dosing unit arranged to dispense a dose of the therapeutic agent to the pump unit. In some examples, the pump unit includes a dosing unit.
[0013] In some examples, the patch pump includes a filtration unit having an inlet end for receiving the therapeutic agent and an outlet end for discharging the therapeutic agent. In some examples, the filter is fixed between the inlet end of the filtration unit and the outlet end of the filtration unit.
[0014] In some examples, the filter unit is disposed upstream of the pump unit. In some cases, the filter unit is disposed downstream of the reservoir unit. In some examples, the filter unit is disposed downstream of the pump unit.
[0015] In some examples, the filtration unit includes an inlet component at an inlet of the filtration unit for receiving the therapeutic agent. In some examples, at least a portion of the inlet component includes a rough inner surface for inducing bubble formation in the therapeutic agent when the therapeutic agent flows over the rough inner surface. In some cases, the inlet component includes a downstream end with a flared / flared profile arranged to direct the therapeutic agent toward the filter. In some examples, the inlet component is arranged to clamp one end of a tubular element for fluidly connecting the delivery unit to the reservoir unit.
[0016] In some examples, the filter unit is arranged to receive the therapeutic agent in a first direction, wherein the filter is fixed at an angle relative to the first direction. In some examples, the filter is fixed at an acute angle relative to the first direction. In some examples, the filter is fixed perpendicularly relative to the first direction. In some examples, the filter is fixed in a parallel manner relative to the first direction.
[0017] In some examples, the filtration unit includes a semi-permeable membrane in fluid communication with the fluid flow path, the semi-permeable membrane being configured to vent gas contained in the fluid flow path.
[0018] In some examples, the filtration unit includes an intermediate medium fixed in the fluid flow path, and the intermediate medium is suitable for inducing bubble formation in the therapeutic agent when the therapeutic agent flows through the intermediate medium. In some examples, the intermediate medium is fixed upstream of the filter. In some examples, the intermediate medium includes a porous section, and the fluid flow path passes through the porous section. In some examples, the intermediate medium includes an open-cell foam, such as a sponge-like material.
[0019] In some examples, the filter is fixed within the delivery unit.
[0020] In some examples, the delivery unit includes an inlet component arranged to receive the therapeutic agent. In some cases, the inlet component includes a downstream end having a flared / flared profile arranged to direct the therapeutic agent toward the filter. In some examples, the inlet component is arranged to clamp one end of a tubular element for fluidly connecting the delivery unit to the reservoir unit.
[0021] In some examples, at least a portion of the inlet component includes a roughened inner surface. In some examples, at least a portion of a downstream end of the inlet component includes a roughened inner surface.
[0022] In some examples, the delivery unit includes an outlet end for receiving an upstream end of the cannula, and a flow redirecting component fixed therein, the flow redirecting component arranged to fluidly connect the inlet component with the upstream end of the cannula. In some examples, the flow redirecting component is arranged to receive the therapeutic agent in a first direction and discharge the therapeutic agent toward the upstream end of the cannula in a second direction different from the first direction. The first direction may be at an acute angle relative to the second direction. The first direction may be at 90 degrees relative to the second direction.
[0023] In some examples, the delivery unit includes a semi-permeable membrane in fluid communication with the fluid flow path, the semi-permeable membrane being configured to vent gas contained in the fluid flow path.
[0024] In some examples, the delivery unit includes an intermediate medium adapted to induce bubble formation within the therapeutic agent. In some examples, the intermediate medium is fixed upstream of the filter. In some examples, the intermediate medium includes a porous section, and the fluid flow path is arranged to pass through the porous section. In some examples, the intermediate medium is fixed upstream of the filter. In some examples, the intermediate medium includes an open-cell foam, such as a sponge-like material.
[0025] In some examples, the patch pump includes a magnetic filtration unit, preferably an electromagnetic filtration unit, which is arranged to apply a magnetic force to the therapeutic agent at one or more predetermined positions along the fluid flow path to filter out one or more charged components / elements from the fluid flow path. In some examples, the electromagnetic filtration unit is powered by a battery unit. In some examples, the pump unit may be arranged to charge one or more particles in the dose of the therapeutic agent. In some examples, a separate charging unit may be provided to charge one or more particles in the therapeutic agent. The applied charge may be a positive charge or a negative charge applied to one or more particles in the dose of the therapeutic agent. In some cases, the porous intermediate medium may be used as an electromagnetic filtration medium and / or a bubble forming medium. In some cases, the electromagnetic filtration unit is arranged to reduce one or more charged particles, such as magnesium and / or calcium, from the therapeutic agent to reduce the hardness of the liquid. In some examples, the magnetic filtration unit includes one or more permanent magnets arranged to apply a magnetic force. Permanent magnets advantageously filter out charged particles, such as iron.
[0026] Also provided is a patch pump for delivering a therapeutic agent to a patient subcutaneously, the patch pump comprising: a reservoir unit for storing the therapeutic agent; a delivery unit having a cannula arranged to deliver the therapeutic agent to the patient subcutaneously; a pump unit for pumping the therapeutic agent along a fluid flow path extending from the reservoir to the cannula; and a magnetic filtration unit, preferably an electromagnetic filtration unit, arranged to apply a magnetic force at one or more predetermined positions along the fluid flow path so as to filter out one or more charged components / elements from the therapeutic agent before the therapeutic agent is delivered to the patient.
[0027] In some examples, the magnetic filtration unit includes an inlet for receiving the therapeutic agent and an outlet for discharging the filtered therapeutic agent. In some cases, the magnetic filtration unit is external to the fluid flow path. In some cases, the magnetic force is applied across the tube containing the therapeutic agent.
[0028] In some examples, the electromagnetic filter unit and the pump unit are connected to a common power supply. In some examples, the common power supply is contained within the pump unit. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Embodiments of the present invention will be further described below with reference to the accompanying drawings, in which:
[0030] Figure 1 is a schematic diagram of an exemplary patch pump housing;
[0031] Figure 2 is a schematic diagram of a first exemplary patch pump;
[0032] Figure 3 is a diagram of an exemplary delivery unit;
[0033] Figure 4 is a perspective cross-sectional view of a first exemplary delivery unit;
[0034] Figure 5A and 5B is a cross-sectional view of a second exemplary delivery unit;
[0035] Figure 6 is a diagram of an exemplary intermediate medium;
[0036] Figure 7 and 8 is a schematic diagram of a second and a third exemplary patch pump;
[0037] Figures 9A to 9C is a schematic diagram of an exemplary filtration unit;
[0038] Fig.10 is a schematic diagram of a fourth exemplary patch pump;
[0039] Fig.11 is a diagram of an exemplary electromagnetic filtering unit. DETAILED DESCRIPTION
[0040] This explanation is particularly suitable for patch pumps, for example, for delivering therapeutic agents such as insulin to patients. However, other applications are also considered, such as cannula access ports and infusion pump systems, such as insulin pumps and infusion devices for CSII treatment. The therapeutic agent can be an insulin drug, such as human insulin or similar insulin. The patch pump described at present is intended to be used for delivering one or more predetermined doses of insulin to patients at a single infusion site in a time period of extension. "Extended time period" used herein should be understood as at least four days. More specifically, the extended time period can include 4 days to 7 days, 7 days or more days, 7 days to 10 days and 10 days or more days. The extended time period can include 14 days or more days. The patch pump can be used for closed-loop systems, and the extended time period can at least equal the wearing time and / or the life span of the CGM device.
[0041] Figure 1 2 is a diagram of an exemplary patch pump housing 10, which includes a plurality of side walls 20, a cover 25 and an adhesive patch 15 for fixing the patch pump housing 10 on the patient's skin. The cover 25 and the side walls 20 define a cavity in which the components necessary for delivering the therapeutic agent 5 can be stored. Obviously, a rectangular housing 10 is not required, and the housing 10 can have other contours. The patch pump typically has no external tube and is a self-contained unit that allows the patient to self-administer and manage their treatment. The patch pump housing 10 can be used with any of the patch pumps described below.
[0042] Figure 2FIG. 2 is a schematic diagram of a first exemplary patch pump, in which the cover 25 is omitted for clarity. Figure 2 There are shown a reservoir unit 100, a pump unit 300, and a delivery unit 400. The tube 200 is used to connect the reservoir unit 100 to the pump unit 300, and to connect the pump unit 300 to the delivery unit 400.
[0043] The reservoir unit 100 contains a therapeutic agent (not shown) prior to delivery to the patient. The illustrated reservoir unit 100 includes only a single fluid port through which the therapeutic agent can be initially filled and can be discharged into the patient in a controlled manner using the pump unit 300. However, it will be apparent that this is not required, and in some cases, the reservoir unit 100 may include multiple fluid ports, such as a dedicated inlet port for filling the reservoir unit 100 and a separate fluid port that can connect the reservoir unit 100 to the tube 200.
[0044] The pump unit 300 is used to pump a dose of the therapeutic agent from the reservoir unit 100 to the delivery unit 400 in a controlled manner to deliver a predetermined dose of the therapeutic agent 5. The pump unit 300 typically includes the batteries and electronics necessary to control and power the electronic components within the patch pump. Figure 2 The pump unit 300 is shown downstream of the reservoir unit 100, but it is clear that this is not necessary, and in some cases, the pump unit 300 may be arranged upstream of the reservoir unit 100. The pump unit 300 may also include a controller for communicating with an external device (e.g., an external device of the patient), so that they can control or adjust the operation of the patch pump as needed. The controller may be part of the pump unit 300, or it may be a different control unit outside the pump unit 300. In some cases, a separate dosing unit (not shown) may be provided to distribute a predetermined dose of the therapeutic agent to the pump unit 300 for delivery as described herein. In some cases, the pump unit 300 can both distribute a predetermined dose of the therapeutic agent and pump a predetermined dose of the therapeutic agent.
[0045] The delivery unit 400 receives the therapeutic agent 5 through the tube 200 and delivers the therapeutic agent 5 to the patient subcutaneously, usually through a cannula 420 fixed to the delivery unit 400, such as Figure 3 shown.
[0046] Figure 34 is a schematic diagram of an exemplary delivery unit 400, which includes a base 405 for accommodating and fixing the remaining components of the delivery unit 400 in place within the patch pump housing 10. These remaining components include a cannula 420, a fluid component 407, through which the therapeutic agent 5 passes to reach the cannula 420, and an inlet component 410, which holds the tube 200 containing the therapeutic agent 5 in place and provides a fluid-tight seal around the tube 200.
[0047] Figure 4 4 is a perspective cross-sectional view of a first exemplary delivery unit 400A. The inlet component 410 includes an inlet for receiving the therapeutic agent 5 from the reservoir unit 100 (e.g., through the tube 200 from the pump unit 300) and an outlet through which the therapeutic agent 5 is directed to a filter 430 fixed within the fluid component 407. The filter 430 removes one or more unwanted substances from the therapeutic agent 5 before the therapeutic agent passes through the flow redirecting component 425 and enters the cannula 420 for delivery to the patient. Although the flow redirecting component 425 is shown to direct the filtered therapeutic agent 5 into the cannula at an angle of approximately 90 degrees, it is clear that this is not required and the flow redirecting component 425 can be arranged differently to direct the fluid in any desired direction relative to the direction in which the filtered therapeutic agent is received. Although the filter 430 is described, this can include one or more filter elements for filtering out specific unwanted substances from the therapeutic agent 5. The inlet component 410 also fixes the filter 430 in an appropriate position within the fluid component 407. The inlet component 410 is shown to be retained by a form-fitting connection, in particular interlocking protrusions and grooves, but it will be apparent that the inlet component 410 may be secured to the fluid component 407 using any chemical or mechanical securing means.
[0048] The inlet member 410 also holds the porous structure 445 upstream of the filter 430 in the fluid member 407. Figure 6 ), the porous structure 445 reduces the fluid pressure within the therapeutic agent 5, and the fluid pressure before the reduction causes dissolved gas to form in the therapeutic agent 5. This advantageously results in the removal of dissolved gas 437 contained in the therapeutic agent before the therapeutic agent is delivered to the patient. It is preferred to remove the bubbles 437 before delivery to reduce the risk of foreign body reaction in the patient. The porous structure 445 triggers the formation of bubbles 437, which can pass through the vent 435 but cannot pass through the filter 430. The semipermeable membrane 440 is fixed to the delivery unit 400 and is in fluid communication with the fluid flow path through the vent 435 for exhausting bubbles from the delivery unit 400. Advantageously, the pressure normally used to pump the therapeutic agent 5 along the fluid flow path is sufficient to force the gas through the semipermeable membrane 440. The semipermeable membrane is preferably a diaphragm that is permeable to gas but impermeable to liquid.
[0049] Although porous structure 445 is described herein, it is apparent that this is only one example of an intermediate medium suitable for inducing bubble formation in the therapeutic agent. By controlling the porosity of porous structure 445, the pressure of therapeutic agent 5 as it passes through delivery unit 400 can also be controlled. An example of porous structure 445 is Figure 6 449 is shown in the figure, where the pores 449 are formed by a series of interconnected pillars 447. The porosity of the porous structure 445 can be controlled in a variety of ways, such as by varying the thickness of the pillars 447 and / or the number of pillars 447. The porous structure 445 can be followed by one or more layers of filter 430 to form a layered structure that limits the ability of gas bubbles to pass through the filter 430 compared to the case where the gas is dissolved in the therapeutic agent 5. The filter 430 may include one or more air-impermeable layers to prevent air from passing through the filter 430. Although the porous structure 445 is described, the intermediate medium may include other structures or functional materials to reduce the fluid pressure in the manner described. For example, the intermediate medium may include any of a honeycomb structure, a mesh structure, a zeolite, or the like.
[0050] Although it is desirable to remove dissolved gases prior to filtering the therapeutic agent 5, one or more other units, such as an exhaust unit, may be included to exhaust any bubbles formed in the therapeutic agent 5 prior to delivery of the therapeutic agent to the patient. As described herein, such an exhaust unit may include a semipermeable membrane in fluid connection with the fluid flow path.
[0051] Independent of the porous structure 445, when the therapeutic agent 5 contacts and passes through the filter 430, this will cause a pressure drop across the filter 430. The upstream of the filter can be considered as a high pressure area 450A, while the downstream of the filter can be considered as a low pressure area 450B (see Figures 9A-9C ). It is in the low pressure region 450B that bubbles may form, which may then be delivered to the patient. Therefore, it is desirable to remove dissolved gases from the therapeutic agent 5 before reaching the filter 430. In addition to or in lieu of providing the porous structure 445, the inlet member 410 may also be provided with a flared / trumpet-shaped opening 412 (see Figure 4 , 5A 5B) to reduce the pressure of the therapeutic agent 5 as it enters the delivery unit 400, thereby forming bubbles. The flared opening 412 causes the fluid pressure of the therapeutic agent 5 to drop as it leaves the inlet component 410, which triggers the formation of bubbles. In the example shown, the effect of the flared opening 412 is enhanced by including a narrowing section upstream of the flared opening 412.
[0052] In addition to or in lieu of the porous structure 445 and / or the flared opening 412, bubble formation may also be induced within the therapeutic agent 5 by passing the therapeutic agent 5 over a rough surface. By increasing the surface roughness of the inlet member 410, this increases the number of nucleation sites on the inner surface of the inlet member 410, which in turn facilitates the formation of bubbles. Obviously, different surface roughness characteristics in the inlet member 410 may be used to control the level of bubble nucleation. The rough surface may be achieved by mechanical abrasion of the inlet member 410 so that a portion or all of the inlet member 410 has a rough surface. In some cases, a first portion of the inlet member 410 may have a first surface roughness parameter, and a second portion of the inlet member 410 may have a second surface roughness parameter different from the first surface roughness parameter to indicate that the second portion has a rougher surface finish than the first portion. The second portion of the inlet member 410 may be a portion of the flared opening 412, or an independent / separate downstream portion located downstream / separate from the inlet of the inlet member 410. Additionally or alternatively, the inlet member 410 may be provided with a plurality of raised surface protrusions that induce turbulence as described above. Thus, while it is desirable to include a porous structure 445 to remove dissolved gases, this is not required. Other materials or structures may be used as an alternative or in addition to a porous structure to induce the formation of bubbles within the therapeutic agent 5. Figure 4 , 5A The delivery units shown in and 5B may be considered integrated delivery and filtration units because they include filter 430 .
[0053] Figure 7 and Figure 8 Schematic diagrams of second and third exemplary patch pumps, both of which include a dedicated filtration unit 500 for filtering therapeutic agent 5. Providing a dedicated filtration unit 500 is advantageous because the unit can be designed to filter the therapeutic agent more effectively than a filter incorporated into another existing unit of a patch pump. Figure 7 The fluid flow path from the reservoir unit 100 to the filter unit 500 and to the pump unit 300 is shown. Figure 8 The fluid flow path is shown from the pump unit 300 to the filter unit 500 and to the delivery unit 400. Obviously, the patch pump may comprise a plurality of filter units 500 in addition to or instead of an integrated delivery and filter unit.
[0054] Figures 9A to 9CSchematic diagram of exemplary filter units 500A-500C. These filter units 500A-500C include an inlet component 410 for connecting the tube 200 to the filter unit and an outlet component for connecting the filter unit 500A-500C to a downstream component (e.g., a pump unit 300 or a delivery unit 400). The function of the inlet component 410 is as described above with respect to the delivery unit 400 and will not be repeated here. The filter units 500A-500C include a filter 430 and a porous structure 445 upstream of the filter 430 to promote the formation of bubbles of the therapeutic agent 5 before reaching the filter 430, as described above. The inlet component 410 connects the tube 200 to the upstream chamber 450A of the filter unit 500A-500C, and any bubbles formed in the upstream chamber 450A are discharged through the semipermeable membrane 440 connected to the fluid of the upstream chamber 450A. Fig.9A The filter 430 and the porous structure 445 are shown arranged perpendicular to the direction in which the fluid flows from the inlet component 410 into the upstream chamber 450A. However, it is desirable to increase the surface area of the filter 430 that can act on the therapeutic agent 5, so the filter unit 500 can be arranged so that the filter 430 and the porous structure 445 are arranged perpendicular to the direction in which the fluid flows from the inlet component 410 into the upstream chamber 450A. Obviously, the filter 430 and / or the porous structure 445 can be arranged independently of each other, and the filter 430 and / or the porous structure 445 can be arranged at an acute angle relative to the direction of fluid flow from the inlet component 410 as desired. An outlet component similar to the inlet component 410 is used to connect the filter units 500A-500C to the downstream pipe 200 to allow the therapeutic agent 5 contained in the downstream chamber 450B to be discharged.
[0055] The porous structure 445 is not necessary and can be removed. Fig. 9C The filter unit 500C does not include the porous structure 445, and as described above, this will cause the dissolved gas to form bubbles in the downstream chamber 450B (i.e., downstream relative to the filter 430) because the filter 430 cannot capture the bubbles 437. In this case, the bubbles in the therapeutic agent should be removed before the therapeutic agent reaches the patient to avoid causing a foreign body reaction. The removal of bubbles can be achieved, for example, by a semipermeable membrane 440 disposed in the delivery unit 400 or in one or more exhaust units as described above.
[0056] Fig.10 It is a schematic diagram of a fourth exemplary patch pump, which includes a reservoir unit 100 , a pump unit 300 , a delivery unit 400 , and an electromagnetic filtration unit 600 , wherein the electromagnetic filtration unit is used to filter charged particles in the therapeutic agent 5 . Fig.10The delivery unit 400 can be any delivery unit described herein. In some cases, the electromagnetic filter unit 600 can be the only filter in the patch pump. The electromagnetic filter unit 600 has an electrical connection to the pump unit 300 so that the pump unit 300 and the electromagnetic filter unit 600 share a common power supply, which is the power supply of the pump unit 300. This is particularly advantageous because the size of the patch pump can be further reduced by not requiring a separate power supply for the electromagnetic filter unit 600. In some cases, the electromagnetic filter unit 600 may include a dedicated power supply that is independent of the power supply used to power the pump unit 300. Fig.10 In the embodiment, the electromagnetic filtration unit 600 is a separate module. However, it is obvious that in some cases, the electromagnetic filtration unit can be embedded in other modules, such as those modules including the filter 430, the delivery unit 400, the pump unit 300 or the reservoir unit 100.
[0057] Fig.11 An exemplary electromagnetic filtration unit 600 including a porous structure 445 is shown. The porous structure 445 can be charged so that charged particles passing through the porous structure 445 adhere to the porous structure and are not delivered to the patient. Particles in the therapeutic agent, such as unwanted substances, can be positively or negatively charged. The particles in the therapeutic agent can be charged at any point upstream of the electromagnetic filtration unit 600. By charging one or more particles in the therapeutic agent, for example by marking any unwanted substances with charged particles, it is possible that any unwanted substances can be filtered out in an effective manner when the therapeutic agent passes through the porous structure 445 due to the greatly increased surface area compared to attaching the particles to the tube 200. This effect is further enhanced by the nonlinear fluid flow path of the electromagnetic filtration unit 600. Although offsetting the inlet and outlet of the electromagnetic filtration unit 600 is one way to achieve a nonlinear fluid flow path, it is clear that this is not necessary, and the porous structure 445 can be designed to direct the fluid flow in a predetermined manner. Although the filter 430 is not included in the electromagnetic filtration unit 600, it is clear that the electromagnetic filtration unit may include a filter.
[0058] A separate battery unit may be provided to power the electromagnetic filtering unit 600, for example to charge one or more unwanted substances in the therapeutic agent and / or to provide electromagnetic forces in the porous structure 445. The electromagnetic field generated within the electromagnetic filtering unit 600 may have a static or dynamic waveform. Although a single controller may be used to control the various units described, it is apparent that this is not required.
[0059] Electromagnetic filter unit 600 may include one or more permanent magnets for filtering out charged particles in the therapeutic agent. One or more filter units 500A-500C may include Fig.10 in a patch pump.
[0060] Above-mentioned patch pump and filtration unit 500A-500C each all comprise filter 430.Filter is intended to for example remove the unwanted substance present in therapeutic agent by filtering, to avoid FBR. " unwanted substance " used herein should be understood as for example one or more substances that may be present in therapeutic agent due to design or accident, and it may not wish to be retained in therapeutic agent when being delivered to infusion site.Especially, filter can remove the unwanted substance that occurs in insulin solution.This unwanted substance can be particulate and / or molecule in essence.The example of the unwanted substance of particle class comprises plastic particle, dust and insulin agglomerate, and they are produced in the manufacture, storage, sterilization or handling process of infusion set and / or insulin solution.The example of unwanted molecular species comprises the preservative that is usually used in insulin solution, for example phenol, cresol (particularly metacresol), benzyl alcohol, benzalkonium chloride, cetrimonium bromide, chlorobutanol, chlorhexidine, chlorocresol, hydroxybenzoate, phenylethyl alcohol, phenoxyethanol and phenylmercuric nitrate.
[0061] The filter may include any filter material capable of removing one or more unwanted substances from the therapeutic agent. To remove particulate unwanted substances, the filter material may provide a physical filter medium for removing unwanted substances by size exclusion, whereby the filter material acts as a molecular sieve. Additionally or alternatively, to remove molecular unwanted substances, the filter material may provide a chemical filter medium for removing unwanted substances by adsorption, such as by adsorption or ion exchange, whereby the filter material binds to the molecular unwanted substances to retain them within the filter. The filter material has a plurality of channels, such as pores (i.e., interconnected hollow spaces), extending therethrough to allow fluid to flow through the filter.
[0062] The filter may be a modular filter, comprising a first and a second sub-filter, the first and second sub-filters being arranged to allow fluid to flow therethrough in series / sequentially for gradually / stepwise / progressively removing different unwanted substances, such as unwanted substances of different sizes and / or different molecular compositions, from the therapeutic agent. Thus, the filter material of the first sub-filter may be different from the filter material of the second sub-filter. The filter may similarly include a third filter, a fourth filter, and so on.
[0063] Suitable filter materials include foams made of cellulose, polyurethane, polyester, polyether, collagen, etc. The foam includes a plurality of channels extending therethrough in the form of interconnected pores to allow fluid to flow through the filter. The foam can be any foam that is capable of removing unwanted particles from the insulin solution. Although foams are described herein, it is apparent that other structures, such as membranes or sheets or the like, may be used in place of the foam, and the properties described in relation to the foam are equally applicable to membranes or sheets.
[0064] Particularly suitable filter materials are disclosed in earlier patent applications including US 4,083,906 and US 1 1 197,949, the contents of which are incorporated herein by reference.
[0065] Suitable filter materials include ion exchange resins, including functionalized porous or gel polymers, which can remove unwanted substances from insulin solutions by gel permeation chromatography processes. In addition, gel polymers can be used to coat channels in filter materials.
[0066] Typically, the filter material may be selected to have at least one material property that facilitates prolonged infusion of insulin at a single infusion site, thereby increasing the wearing time, for example at least 4 days, including 4 to 7 days, 7 days or more days, 7 to 10 days, 10 days or more days, and 14 days or more days.
[0067] Throughout the description and claims of this specification, the words "comprise" and "comprising" and their variations mean "including but not limited to", and they are not intended to (and do not) exclude other parts, additives, ingredients, integral bodies or steps. Throughout the description and claims of this specification, the singular (a / an) includes the plural, unless the context requires otherwise. In particular, where the indefinite article is used, the specification should be understood as considering the plural as well as the singular, unless the context requires otherwise.
[0068] Features, integers, characteristics or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all steps of any method or process so disclosed, may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The invention is not limited to the details of any foregoing embodiments. The invention extends to any novel one or any novel combination of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one or any novel combination of the steps of any method or process so disclosed.
Claims
1. A patch pump for delivering a therapeutic agent to a patient subcutaneously, the patch pump comprising: a reservoir unit configured to store a therapeutic agent; a delivery unit having a cannula arranged to subcutaneously deliver a therapeutic agent to a patient; a pump unit arranged to pump a therapeutic agent along a fluid flow path extending from the reservoir unit to the cannula; as well as A filter is secured in the fluid flow path and is configured to filter the therapeutic agent prior to delivery to a patient.
2. The patch pump according to claim 1, wherein: The filter is fixed within the reservoir unit.
3. The patch pump according to claim 1 or 2, wherein: The reservoir unit is arranged to receive a therapeutic agent from an external source.
4. A patch pump according to any one of the preceding claims, wherein: The filter is fixed within the pump unit.
5. The patch pump according to any one of the preceding claims, further comprising a filtration unit having an inlet for receiving the therapeutic agent and an outlet for discharging the therapeutic agent, wherein the filter is fixed between the inlet of the filtration unit and the outlet of the filtration unit.
6. The patch pump according to claim 5, wherein: The filter unit is disposed upstream of the pump unit.
7. The patch pump according to claim 5, wherein: The filter unit is disposed downstream of the pump unit.
8. The patch pump according to any one of claims 5 to 7, wherein: The filtration unit includes an inlet component for receiving the therapeutic agent at an inlet of the filtration unit, wherein at least a portion of the inlet component includes a rough inner surface for inducing bubble formation in the therapeutic agent as the therapeutic agent flows over the rough inner surface.
9. The patch pump according to any one of claims 5 to 8, wherein: The filter unit is arranged to receive a therapeutic agent in a first direction, wherein the filter is fixed at an angle relative to the first direction.
10. The patch pump according to any one of claims 5 to 9, wherein: The filtration unit includes a semi-permeable membrane in fluid communication with the fluid flow path and configured to discharge gas contained within the fluid flow path.
11. The patch pump according to any one of claims 5 to 10, wherein: The filtration unit includes an intermediate medium fixed in the fluid flow path, wherein the intermediate medium is adapted to induce bubble formation within the therapeutic agent as the therapeutic agent flows through the intermediate medium.
12. A patch pump according to any one of the preceding claims, wherein: The filter is fixed in the delivery unit.
13. The patch pump according to claim 12, wherein: The delivery unit comprises an inlet component arranged to receive a therapeutic agent, wherein the inlet component comprises a downstream end having a flared profile arranged to direct the therapeutic agent towards the filter.
14. The patch pump according to claim 13, wherein: At least a portion of the inlet member includes a roughened inner surface.
15. The patch pump according to any one of claims 12 to 14, wherein: The conveying unit comprises: an outlet port for receiving the upstream end of the cannula; and a flow redirecting member fixed in the delivery unit and arranged to fluidically connect the inlet member with the upstream end of the cannula, The flow redirecting component is arranged to receive the therapeutic agent in a first direction and to discharge the therapeutic agent in a second direction different from the first direction toward the upstream end of the cannula.
16. The patch pump according to any one of claims 12 to 15, wherein: The delivery unit includes a semi-permeable membrane in fluid communication with the fluid flow path and configured to discharge gas contained within the fluid flow path.
17. The patch pump according to any one of claims 12 to 16, wherein: The delivery unit includes an intermediate medium suitable for inducing bubble formation within the therapeutic agent.
18. A patch pump according to any one of the preceding claims, comprising an electromagnetic filtration unit arranged to apply a magnetic force to the therapeutic agent at one or more predetermined locations along the fluid flow path to filter out one or more charged components from within the fluid flow path.
19. The patch pump according to claim 18, wherein: The electromagnetic filtering unit and the pump unit are connected to a common power source.
20. The patch pump according to claim 19, wherein: The common power supply is contained within the pump unit.
21. A patch pump for subcutaneously delivering a therapeutic agent to a patient, the patch pump comprising: a reservoir unit for storing a therapeutic agent; a delivery unit having a cannula arranged to subcutaneously deliver a therapeutic agent to a patient; a pump unit arranged to pump the therapeutic agent along a fluid flow path extending from the reservoir to the cannula; as well as A magnetic filtration unit is arranged to apply a magnetic force at one or more predetermined locations along the fluid flow path to filter out one or more charged components from the therapeutic agent before the therapeutic agent is delivered to the patient.
22. The patch pump according to claim 21, wherein: The magnetic filter unit is an electromagnetic filter unit.
23. The patch pump according to claim 21 or 22, wherein: The magnetic filtration unit includes an inlet for receiving a therapeutic agent and an outlet for discharging the filtered therapeutic agent.
24. A patch pump according to any one of claims 21 to 23, wherein: The magnetic filter unit is external to the fluid flow path.
25. The patch pump according to any one of claims 21 to 24, wherein: The magnetic force is applied across the tube containing the therapeutic agent.
26. The patch pump according to claim 22, wherein: The electromagnetic filtering unit and the pump unit are connected to a common power source.
27. The patch pump according to claim 26, wherein: The common power supply is contained within the pump unit.
